Too many things can go right at these price levelsGiven the many possible good surpises that can occur, may it be Nash combo partnership with Big Pharma given renewed interest in the Nash drugs or Trogarzo companion opportunity with Gilead new drug. Also any kind of life out of the Sort-1 platform will stir the soul of shareholders. Until then we have growing sales from legacy drugs and the sales structure is pretty decent now. At these price levels it qualifies as a stupid buy whatever the doom sayers will come up with to justify their frustrations or the sale they made in panic.